Characterization of poliovirus variants selected for resistance to the antiviral compound V-073

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 11, 2012, Pages 5568-5574

  Liu, Hong Mei ^a   Roberts, Jason A ^b   Moore, Deborah ^a   Anderson, Barbara ^a   Pallansch, Mark A ^a   Pevear, Daniel C ^c   Collett, Marc S ^d   Oberste, M Steven ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

^c VenatoRx Pharmaceuticals Inc   (United States)

^d ViroDefense Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ANTIVIRUS AGENT; ISOLEUCINE; METHIONINE; PHENYLALANINE; UNCLASSIFIED DRUG; V 073;

AMINO ACID ANALYSIS; AMINO ACID SUBSTITUTION; AMPLICON; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CONTROLLED STUDY; GENETIC VARIABILITY; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; POLIOMYELITIS VIRUS 1; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; VIRION; VIRUS CAPSID; VIRUS INFECTIVITY; VIRUS ISOLATION;

AMINO ACID SUBSTITUTION; AMINO ACIDS; ANIMALS; ANTIVIRAL AGENTS; CAPSID; CAPSID PROTEINS; CELL LINE; DRUG RESISTANCE, VIRAL; HALOGENATED DIPHENYL ETHERS; HUMANS; MACACA MULATTA; MUTATION; POLIOVIRUS; VIRAL PLAQUE ASSAY;

EID: 84868010690     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00539-12     Document Type: Article

References (18)

1. Alexander LN, et al. 2004. Vaccine policy changes and epidemiology of poliomyelitis in the United States. JAMA 292:1696-1701.
2. Anonymous. 2005. Cessation of routine oral polio vaccine (OPV) use after global polio eradication: framework for national policy makers in OPV-using countries, p 12. World Health Organization, Geneva, Switzerland.
3. Buontempo PJ, et al. 1997. SCH 48973: a potent, broad-spectrum, anti-enterovirus compound. Antimicrob. Agents Chemother. 41:1220-1225.
4. Collett MS, Neyts J, Modlin JF. 2008. A case for developing antiviral drugs against polio. Antivir. Res. 79:179-187.
5. Committee on Development of a Polio Antiviral and Its Potential Role in Global Poliomyelitis Eradication. 2006. Exploring the role of antiviral drugs in the eradication of polio. National Research Council, Washington, DC.
6. Groarke JM, Pevear DC. 1999. Attenuated virulence of pleconaril-resistant coxsackievirus B3 variants. J. Infect. Dis. 179:1538-1541.
7. Heinz BA, et al. 1989. Genetic and molecular analyses of spontaneous mutants of human rhinovirus 14 that are resistant to an antiviral compound. J. Virol. 63:2476-2485.
8. Humphrey W, Dalke A, Schulten K. 1996. VMD: visual molecular dynamics. J. Mol. Graphics 14:33-38.
9. Kouiavskaia DV, et al. 2011. Immunologic and pathogenic properties of poliovirus variants selected for resistance to antiviral drug V-073. Antivir. Ther. 16:999-1004.
10. Lentz KN, et al. 1997. Structure of poliovirus type 2 Lansing complexed with antiviral agent SCH48973: comparison of the structural and biological properties of three poliovirus serotypes. Structure 5:961-978.
11. Mosser AG, Rueckert RR. 1993. WIN 51711-dependent mutants of poliovirus type 3: evidence that virions decay after release from cells unless drug is present. J. Virol. 67:1246-1254.
12. Mosser AG, Sgro J-Y, Rueckert RR. 1994. Distribution of drug resistance mutations in type 3 poliovirus identifies three regions involved in uncoating functions. J. Virol. 68:8193-8201.
13. Mosser AG, Shepard DA, Rueckert RR. 1994. Use of drug-resistance mutants to identify functional regions in picornavirus capsid proteins. Arch. Virol. Suppl. 9:111-119.
14. Oberste MS, et al. 2009. In vitro antiviral activity of V-073 against polioviruses. Antimicrob. Agents Chemother. 53:4501-4503.
15. Pevear DC, Tull TM, Seipel ME, Groarke JM. 1999. Activity of pleconaril against enteroviruses. Antimicrob. Agents Chemother. 43: 2109-2115.
16. Phillips JC, et al. 2005. Scalable molecular dynamics with NAMD. J. Comput. Chem. 26:1781-1802.
17. Schwede T, Kopp J, Guex N, Peitsch MC. 2003. SWISS-MODEL: an automated protein homology-modeling server. Nucleic Acids Res. 31: 3381-3385.
18. Zoete V, Cuendet MA, Grosdidier A, Michielin O. 2011. SwissParam, a fast force field generation tool for small organic molecules. J. Comput. Chem. 32:2359-2368.